IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER
Por:
Jimenez-Lima, Roberto, Arango-Bravo, Eder, Galicia-Carmona, Tatiana, Lino-Silva, Leonardo S., Trejo-Duran, Guadalupe E., Alvarado-Silva, Cristina, Castañeda-Renderos O.H., Vanoye-Carlo, Elva G., Torre C.F., Dueñas-González A., Cetina-Perez, Lucely
Publicada:
1 jul 2020
Categoría:
Medicine (miscellaneous)
Resumen:
Cervical cancer (CC) is one of the most common gynecological tumors and
an important health problem, especially in developing countries. The
vast majority of patients in early stages are cured of the disease with
surgical treatment and with concomitant chemoradiotherapy in locally
advanced stages. However, in patients with recurrent, persistent, or
metastatic cervical CC, the effectiveness of treatment is limited,
except for the combination of chemotherapy based on platinum doublets
plus bevacizumab, the treatment that has achieved the best results to
date. Programmed cell death-1/PD ligand-1 (PD-1/PD-L1) inhibitors could
be a novel and cutting-edge therapeutic option to improve clinical
outcomes in this group of patients. Thus far, there are a few Phase I/II
clinical trials that have assessed the usefulness of pembrolizumab and
nivolumab in this group of patients; these include the KEYNOTE 028,
KEYNOTE 158, and CHECKMATE 358 trials, in which clinical benefit has
been proven with PD-1/PD-L1 inhibitors in recurrent, persistent, or
metastatic CC, as second-line treatment. There are also some ongoing
trials that could provide further evidence on the PD-1/PD-L1 pathway as
a therapeutic target in CC. In this review, we will focus on the
usefulness of these PD-1/PDL1 inhibitors in CC, as well as on trials
that are still in the recruitment phase, to confirm their effectiveness
in this clinical setting.
Filiaciones:
Jimenez-Lima, Roberto:
Faculty of Medicine, Doctorate Program in Medical, Dental and Health Sciences, Universidad Nacional Autónoma de México (UNAM)Mexico City, Mexico
Department of Clinical Research, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Arango-Bravo, Eder:
Department of Clinical Research, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Department of Medical Oncology, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Galicia-Carmona, Tatiana:
Department of Clinical Research, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Department of Medical Oncology, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Lino-Silva, Leonardo S.:
Department of Oncologic Pathology, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Trejo-Duran, Guadalupe E.:
Department of Radiotherapy, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Alvarado-Silva, Cristina:
Department of Medical Oncology, Hospital Juárez de MéxicoMexico City, Mexico
Castañeda-Renderos O.H.:
Department of Medical Oncology, Hospital Universitario de Saltillo, Coah., Mexico
Vanoye-Carlo, Elva G.:
Department of Gynecologic Oncology, Hospital General Agustín O'Horan Mérida, Mexico
Torre C.F.:
Department of Medical Oncology, Centro Estatal de Oncología Campeche INDESALUD, Camp, Mexico
Dueñas-González A.:
Department of Clinical Research, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Department of Medical Oncology, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Cetina-Perez, Lucely:
Department of Clinical Research, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
Department of Medical Oncology, Instituto Nacional de Cancerología (INCan)Mexico City, Mexico
|